BioFuse Medical Technologies Welcomes New Member, Joseph Stauffer, DO, MBA, FAPCR to the Board of Directors


MELBOURNE, FL/ACCESSWIRE/June 8, 2022/ BioFuse Medical Technologies, Inc., an emerging surgical device company with transformative tissue sealing and welding technology, today announced that Joseph Stauffer, DO, MBA, FAPCR, is joining the Board of Directors of the society. Dr. Stauffer is a Biotechnology Executive Physician and President/Founder of Alta Life Sciences, LLC., a pharmaceutical advisory/investment firm based in Sarasota, Florida. He is currently Medical Director of Antibe Therapeutics, a public biotech company based in Toronto.

“We are thrilled to have Dr. Stauffer on the BioFuse team,” said Gary Henley, Chairman of BioFuse’s Board of Directors. “Dr. Stauffer has a long career working with companies to develop and commercialize new technology medical products that are of great benefit to patients. His career as a physician, his experience as an FDA reviewer and his high-level roles in the industry give him unique knowledge of the new medical device market. We are pleased to have him on hand to share this knowledge with us as we move forward with our exciting BioFuse technology.”

Dr. Stauffer said, “It is a privilege and an honor to serve on the Board of Directors of BioFuse Medical Technologies. I look forward to working with this seasoned group of industry expert operators to drive SurgiFuse forward.® technology to meet surgical and unmet patient needs.

Since 2004, Dr. Stauffer has served as medical director in public and private specialty device, pharmaceutical and biotechnology companies. Dr. Stauffer’s experience in medical practice and clinical research spans over 25 years; having built teams of physicians, scientists, medical science liaisons, regulators and safety experts in support of clinical development projects, marketed branded drugs and devices. He was intimately involved in raising a total of $650 million in new equity and/or deal-related financing between 2010 and 2021 at four different companies.

Prior to beginning his career in industry and rising to the position of Global Medical Director at Abbott Labs, he worked at the FDA as a Medical Review Officer in the Anti-Inflammatory and Analgesic Division of the Center for Drug Evaluation and Research. He was a founding member in 2002 of the Initiative on Methods, Measurement and Assessment of Pain in Clinical Trials (IMPACT). In 2011, as part of the FDA’s Critical Path initiative, this collaboration became a formal public-private partnership between the pharmaceutical industry, FDA, NIH, universities and patient advocacy groups. The new group, Analgesic Clinical Trial Translations, Innovations, Opportunities and Networks (ACTTION) is an ongoing, multi-year effort designed to address key scientific information gaps that confuse clinical trials and drug/device development. He has lectured internationally on topics ranging from clinical drug/device research, medical affairs, investor relations, and the FDA regulatory process.

Dr. Stauffer received his medical degree from the Philadelphia College of Osteopathic Medicine. He completed his residency in Anesthesiology and Critical Care Medicine at Johns Hopkins University Hospital and maintained a part-time assistant professorship in the Department of Anesthesiology and Critical Care Medicine at the university’s medical school. Johns Hopkins until 2016. His MBA is from a joint program (TRIUM) between New York University, Stern School of Business, London School of Economics (LSE) and HEC (High commercial studies) School of Management in Paris. Dr. Stauffer is a US Navy veteran; honorably discharged as a lieutenant commander after serving 10 years as a naval doctor. He maintains an active physician’s license from Pennsylvania.

To learn more about BioFuse Medical Technologies, Inc., visit biofusemedical.com

###

About BioFuse Medical Technologies, Inc.

BioFuse™ is a new RF tissue sealing and welding technology. Using transformative technology, proven in Europe in thousands of cases, this surgical innovation replaces traditional methods of suturing, stapling and electrosurgical vessel sealing. BioFuse™ technology can address a wide range of clinical applications, features a robust pipeline of products in various stages of development, and has FDA 510k clearance for vessel sealing, strong IP protection, and trade secrets.

This technology will serve a large, growing $3 billion target market. Market data indicates a strong and growing demand for advanced and innovative devices that facilitate the evolution of surgical intervention techniques and significantly improve patient outcomes. Surgeons are looking for new solutions, new technology that will eliminate scarring and reduce infection rates.

BioFuse Medical Technologies, Inc. is privately held and interested accredited investors can learn more about the company’s 506(c) offering investment opportunities by visiting: biofusemedical.com

About SurgiFuse®

SurgiFuse® is the core technology developed by BioFuse Medical Technologies. It is an advanced high frequency electrosurgical system available and incorporates a unique and proprietary means of controlling and delivering energy to and through the target tissue. In studies, SurgiFuse® tissue fusion has been shown to be stronger than mechanical closure, creates a continuous seam in the tissue, and leaves no foreign bodies behind. SurgiFuse® encompasses the exclusive use of low voltages and high currents, optimized specifically for the tissue to be fused. In addition, the outflow of energy to the tissue occurs in pulses. These computer-controlled pulses of energy create optimal temperatures that unravel large molecules in tissue, and as these molecules cool, they intertwine and create fusion. For more information about BioFuse™, please visit www.BioFuseMedical.com.

Contact:

Scott Sander, President
BioFuse Medical Technologies, Inc.
[email protected]

THE SOURCE: BioFuse Medical Technologies, Inc.

See the source version on accesswire.com:
https://www.accesswire.com/704082/BioFuse-Medical-Technologies-Welcomes-New-Member-Joseph-Stauffer-DO-MBA-FAPCR-to-the-Board-of-Directors

Previous Texas reports first case of monkeypox in Dallas County
Next AfDB Approves $4.3 Billion Loans for Southern Commuter Rail Project